ERBB2 and adenocarcinoma: This is a Phase 2, signal-generating, open-label, 2-arm, non-randomized study in adult patients with metastatic HER2/neu-overexpressing gastric cancer (GC) or GEJ adenocarcinomas are planned to be conducted at sites in Australia and the US.